Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2008-07-15
2008-07-15
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
07399787
ABSTRACT:
The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 5055608 (1991-10-01), Marks et al.
patent: 5175191 (1992-12-01), Marks et al.
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5608108 (1997-03-01), Marks et al.
patent: 5654333 (1997-08-01), Samid
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5773474 (1998-06-01), Breslow et al.
patent: 5932616 (1999-08-01), Breslow et al.
patent: 6087367 (2000-07-01), Breslow et al.
patent: 6231880 (2001-05-01), Perrine
patent: 6239176 (2001-05-01), Nudelman et al.
patent: 6262116 (2001-07-01), Pandolfi et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6495719 (2002-12-01), Lan-Hargest et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: RE38506 (2004-04-01), Breslow et al.
patent: 6905669 (2005-06-01), DiMartino
patent: 2003/0082666 (2003-05-01), Kammer et al.
patent: 2003/0114525 (2003-06-01), Kammer et al.
patent: 2003/0161830 (2003-08-01), Jackson et al.
patent: 2003/0235588 (2003-12-01), Richon et al.
patent: 2004/0002506 (2004-01-01), Breslow et al.
patent: 2004/0018968 (2004-01-01), Sgouros
patent: 2004/0072735 (2004-04-01), Richon et al.
patent: 2004/0087631 (2004-05-01), Bacopoulos et al.
patent: 2004/0122101 (2004-06-01), Miller et al.
patent: 2004/0127522 (2004-07-01), Chiao et al.
patent: 2004/0127523 (2004-07-01), Bacopoulos et al.
patent: 2004/0132643 (2004-07-01), Fojo et al.
patent: 2004/0132825 (2004-07-01), Bacopoulos et al.
patent: 2004/0167184 (2004-08-01), Wiech et al.
patent: 2004/0266818 (2004-12-01), Breslow et al.
patent: 2005/0004007 (2005-01-01), Grant et al.
patent: 2006/0167103 (2006-07-01), Bacopoulos et al.
patent: 2006/0276547 (2006-12-01), Bacopoulos et al.
patent: 2007/0060614 (2007-03-01), Bacopoulos et al.
patent: 2007/0190022 (2007-08-01), Bacopoulos et al.
patent: 0547000 (2003-06-01), None
patent: WO 95/31977 (1995-11-01), None
patent: WO 98/39965 (1998-09-01), None
patent: WO 98/40080 (1998-09-01), None
patent: WO 98/55449 (1998-12-01), None
patent: WO 00/21979 (2000-04-01), None
patent: WO 00/71703 (2000-11-01), None
patent: WO 01/16106 (2001-03-01), None
patent: WO 01/18171 (2001-03-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 01/70675 (2001-09-01), None
patent: WO 02/15921 (2002-02-01), None
patent: WO 02/22577 (2002-03-01), None
patent: WO 02/30879 (2002-04-01), None
patent: WO 02/46144 (2002-06-01), None
patent: WO 02/055017 (2002-07-01), None
patent: WO 02/085400 (2002-10-01), None
Rubartelli et al. Cancer Research, 1995, vol. 55, pp. 675-680.
“Aton Pharma, Inc. Announces Initiation of Two Phase II Trials to Evaluate Efficacy of HDAC Inhibitor SAHA”, Oct. 30, 2002.
“Aton Pharma, Inc. Announces Phase I Clinical Trial of SAHA in Advanced Leukemias”, Jul. 1, 2003.
“Aton Pharma, Inc. Appoints Judy H. Chiao, M.D., as Vice President, Oncology Clinical Research and Development”, Sep. 20, 2002.
“Aton Pharma, Inc. Presents Phase I Trial Data of Anti-Cancer Agent SAHA in Patients with hematological Malignancy at ASCO”, Jun. 2, 2003.
“Aton Pharma, Inc. Presents Phase I Trial Data on Anti-Cancer Agent SAHA and EORTC/NCI/AACR Symposium”, Nov. 21, 2002.
“Aton Pharma, Inc. Received Orphan Drug Designation for SAHA in Multiple Myeloma and Initiates Phase I Trial”, Oct. 13, 2003.
“Aton Pharma, Inc. Reports on Phase I Trail of SAHA”, Aug. 14, 2002.
Adhikari, D et al. Proceedings of the American Association for Cancer Research Annual Meeting, (1998), vol. 39, p. 312, “Radiosensitization of Lymphoma Cell Lines by Sodium Butyrate”.
Alexandrov, I et al., FEBS Letters, (1998), vol. 434, pp. 209-214, “Sodium Butyrate Suppresses Apoptosis in Human Burkitt Lymphomas and Murine Plasmacytomas Bearing c-myc Translocations”.
Almenara, J. et al., Leukemia (2002), vol. 16, pp. 1331-1343, “Synergistic Induction of Mitochondrial Damage and Apoptosis in Human Leukemia Cells by Flavopiridol and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA)”.
Amin Hm et al., British Journal of Haematology (2001), vol. 115, pp. 287-297, “Histone Deacetylase Inhibitors Induce Caspase-Dependent Apoptosis and Downregulation of Daxx in Acute Promyeloytic Leukaemia with t(15;17)”.
Aron, JL et al., Blood (2003), vol. 102, No. 2, pp. 652-658, “Depsipeptide (FR901228) Induces Histone Acetylation and Inhibition of Histone Deacetylase in Chronic Lymphocytic Leukemia Cells Concurrent With Activation of Caspase 8-mediated Apoptosis and Down-Regulation of c-FLIP Protein”.
Benoit, NE et al., Immunopharmacology, (1996), vol. 35, pp. 129-139, “Increased inhibition of Proliferation of Human B Cell Lymphomas Following Litigation of CD40, and Either CD19, CD20, CD95 or Surface Immunoglobulin”.
Bode, J et al., Journal of Interferon Research, (1982), vol. 2, No. 2, pp. 159-166, “Links Between Effectsof Butyrate on Histone Hyperacetylation and Regulation of Interferon Synthesis in Namalva and FS-4 Cell Lines”.
Buckley, AR et al., Cell Growth & Differentiation (1996), vol. 7, pp. 1713-1721, “Alteration in pim-1 and c-myc Expression Assoicated with Sodium Butyrate-induced Growth Factor Dependency in Autonomous Rat Nb2 Lymphoma Cells”.
Buckley, AR et al., Proceedings of the American Association for Cancer Research Annual Meeting, (1997), vol. 38, p. 193, “Reversal of Apoptosis Resistance by Butyrate in rat Nb2 Lymphoma Cells”.
Byrd, JC et al., Blood (1999), vol. 94, No. 4, pp. 1401-1408, “Depsipeptide (FR901228): A Novel Therapeutic Agent with Selective, In Vitro Activity Against Human B-Cell Lymphocytic Leukemia Cells”.
Cao, et al. (2001), Am. J. Respir. Cell Mol. Biol., 25:562-8, “Histone Deacetylase Inhibitor Downregulation of bcl-xl Gene Expression Leads to Apoptosis Cell Death in Mesothelioma”.
Carducci, MA et al., Clinical Cancer Research (2001), vol. 7, No. 10 pp. 3047-3055, “A Phase I Clincal and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule”.
Dear, AE et al., Biochimica et Biophysics Acta, (2000), vol. 1492, pp. 15-22, “The Novel Anti-Tumor Agent Oxamfatin Differentially Regulates Urokinase and Plasminogen Activator Inhibitor Type 2 Expression and Inhibits Urokinase-Mediated Proteolytic Activity”.
Desai, D et al., Anticancer Research (2003), vol. 23, pp. 499-504, “Chemopreventive Efficacy of Suberoylanilide Hydroxamic Acid (SAHA) Against 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced Lung Tumorigenesis in Female A/J Mice”.
Dhordain, P et al., Nucleic Acids Research, (1998), vol. 26, No. 20, pp. 4645-4651, “The LAZ3(BCL-6) Oncoprotein Recruits a SMRT/mSIN3A/Histone Deacetylase Containing Complex to Mediate Transcriptional Repression”.
Edelman, MJ et al., Cancer Chemotherapy and Pharmacology (2003), vol. 51, pp. 439-444, “Clinical and Pharmacologic Study of Tributyrin: An Oral Butyrate Prodrug”.
Feinman, R et al., Blood (2002), vol. 100, No. 11, pp Abstract 3195, “The Histone Deacetylast Inhibitor, Suberoylanilide Hydroxyamic Acid, Induces Apoptosis of Multiple Myeloma Cells”.
Fillppovich, I et a
Bacopoulos Nicholas G.
Chiao Judy H.
Miller Thomas A.
Paradise Carolyn M.
Richon Victoria M.
Anderson James D
Elrifi, Esq. Ivor R.
Marschel Ardin
Merck HDAC Research, LLC
Mintz Levin Cohn Ferris Glovsky and Popeo PC
LandOfFree
Methods of treating cancer with HDAC inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating cancer with HDAC inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cancer with HDAC inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2774382